The core activity of ReproNovo is the development of innovative solutions for reproductive medicine and women's health, particularly the treatment of infertility and adenomyosis. The company focuses on developing therapeutic approaches to improve the success rates of assisted reproductive technologies and to develop new treatment options for men with hypogonadism and women with adenomyosis.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of Therapies for Fertility and Gynaecology
Development of new therapeutic solutions for male and female fertility as well as gynaecology, focusing on unmet medical needs and indications that are insufficiently treated.
Therapy Development for Male Fertility
Oral drug programmes for the treatment of male infertility with low testosterone, to promote sperm production and improve the chances of pregnancy.
Therapy Development for Embryo Implantation
Oral therapy to improve embryo implantation following ART, with the aim of increasing pregnancy and live birth rates.
Therapy Development for Adenomyosis
Oral, non-surgical treatment of adenomyosis symptoms, in particular to relieve dysmenorrhoea and other uterine complaints.
In-licensing and Out-licensing
Partnerships for in-licensing and out-licensing of programmes in fertility and gynaecology, including strategic alliances for advanced clinical assets.